Traws Pharma (TRAW) Stock Price, News & Analysis

Company Overview

Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products.

Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections. The company is also developing oncology candidate narazaciclib, a next-generation cyclin-dependent kinase 4/6 inhibitor being studied for potential use in cancer treatment.

The company was formerly known as Onconova Therapeutics, Inc. and adopted the Traws Pharma name as it expanded its focus to include respiratory antiviral development. Traws Pharma is headquartered in Newtown, Pennsylvania, and conducts research and clinical development activities intended to support potential treatment applications in international markets.

Key Stats

• Today's Range: $0.52 to $0.54
• 50-Day Range: $0.44 to $0.63
• 52-Week Range: $0.43 to $3.27
• Volume: 52,950 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $8.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Reduce

Traws Pharma Stock Analysis - MarketRank™

Traws Pharma scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Traws Pharma has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Traws Pharma has a consensus price target of $1.00, representing about 86.6% upside from its current price of $0.54.

Amount of Analyst Coverage

Traws Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Traws Pharma are expected to decrease in the coming year, from ($1.20) to ($1.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Traws Pharma is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Traws Pharma is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.31% of the float of Traws Pharma has been sold short.

Short Interest Ratio / Days to Cover

Traws Pharma has a short interest ratio ("days to cover") of 8.61.

Change versus previous month

Short interest in Traws Pharma has recently decreased by 3.35%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Traws Pharma does not currently pay a dividend.

Dividend Growth

Traws Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Traws Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

6 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Traws Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.57% of the stock of Traws Pharma is held by insiders.

Percentage Held by Institutions

7.95% of the stock of Traws Pharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TRAW
• Previous Symbol: NASDAQ:TRAW
• CIK: 1130598
• Web: www.trawspharma.com
• Phone: 267-759-3680
• Fax: 267-759-3681
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Traws Pharma: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +90.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $9.17 million
• Net Margins: N/A
• Pretax Margin: -710.83%
• Return on Equity: -23,868.92%
• Return on Assets: -165.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.93
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.71 per share
• Price / Cash Flow: 0.74
• Book Value: ($0.07) per share
• Price / Book: -7.51

Miscellaneous

• Outstanding Shares: 15,368,000
• Free Float: 14,205,000
• Market Cap: $8.08 million
• Optionable: No Data
• Beta: 1.52